Skip to content

Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement

Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03506347
Enrollment
24
Registered
2018-04-24
Start date
2018-09-24
Completion date
2019-01-17
Last updated
2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthropathy of Knee Joint

Brief summary

The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at obtaining adequate tissue levels of the antibiotic than the current standard dose which is given intravenously (IV) through a wrist vein. The use of intraosseous regional administration (IORA) of vancomycin requires the use of a tourniquet for the duration of the procedure. Many surgeons prefer to perform the surgery with tourniquet use minimised or without a tourniquet at all. The aim of this study is to evaluate whether IORA vancomycin can achieve effective tissue concentrations with tourniquet use minimised.

Detailed description

Patients are assigned to one of two groups by chance (like a coin toss): GROUP A - Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. GROUP B - Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated. Both Groups will receive weight-based dose of systemic cefazolin ( or alternative antibiotic if allergic to cefazolin 15 minutes prior to inflation of tourniquet. This ensures all patients in the study receive effective antibiotic prophylaxis regardless of randomization. Both groups of patients would then undergo routine prep and draping For both groups, Total knee replacement would then be carried out as normal and the tourniquet will be inflated for cementation of the implants. TISSUE SAMPLES Ten (10) tissue samples will be taken from each patient, 6 'fat' samples and 4 'bone' samples. Each sample is very small, around the size of a pinhead. Bone samples will be taken from the femur only to ensure no direct contamination from the site of injection (tibia) In addition, drain samples will be taken from the intra-articular drain site to measure vancomycin concentration the morning following surgery. Three blood samples will be taken in both groups, intraoperatively, in recovery, and the following morning. These samples are frozen and sent to a lab for analysis.

Interventions

DRUGVancomycin

Antibiotic

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Primary Total Knee Arthroplasty for osteoarthritis Informed consent given

Exclusion criteria

Current or treatment with IV Vancomycin within preceding 7 days Previous hypersensitivity to vancomycin Significant cardiac or respiratory abnormality Patient has contraindications to IO vascular access using the EZ-IO

Design outcomes

Primary

MeasureTime frameDescription
Vancomycin Concentration in FatApproximately 60 minutes post surgical incisionMean vancomycin concentration in fat measured in ug/g at surgical closure
Vancomycin Concentration in BoneApproximately 60 minutes post surgical incisionMean vancomycin concentration in bone measured in ug/g at surgical closure

Countries

United States

Participant flow

Participants by arm

ArmCount
Vancomycin 15mg/kg IV
Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery. Vancomycin: Antibiotic
12
Vancomycin 500mg Intraosseous
Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated. Vancomycin: Antibiotic
12
Total24

Baseline characteristics

CharacteristicVancomycin 500mg IntraosseousTotalVancomycin 15mg/kg IV
Age, Continuous69.1 years
STANDARD_DEVIATION 8.15
68 years
STANDARD_DEVIATION 8.07
68 years
STANDARD_DEVIATION 8.29
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
12 participants24 participants12 participants
Sex: Female, Male
Female
5 Participants12 Participants7 Participants
Sex: Female, Male
Male
7 Participants12 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 12
other
Total, other adverse events
0 / 120 / 12
serious
Total, serious adverse events
0 / 120 / 12

Outcome results

Primary

Vancomycin Concentration in Bone

Mean vancomycin concentration in bone measured in ug/g at surgical closure

Time frame: Approximately 60 minutes post surgical incision

ArmMeasureValue (MEAN)Dispersion
Vancomycin 15mg/kg IVVancomycin Concentration in Bone8.3 ug/gStandard Deviation 0.77
Vancomycin 500mg IntraosseousVancomycin Concentration in Bone26.9 ug/gStandard Deviation 1.31
p-value: 0.009ANOVA
Primary

Vancomycin Concentration in Fat

Mean vancomycin concentration in fat measured in ug/g at surgical closure

Time frame: Approximately 60 minutes post surgical incision

ArmMeasureValue (MEAN)Dispersion
Vancomycin 15mg/kg IVVancomycin Concentration in Fat6.0 ug/gStandard Deviation 0.85
Vancomycin 500mg IntraosseousVancomycin Concentration in Fat40.5 ug/gStandard Deviation 8.08
p-value: 0.001ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026